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Protective role of the skin is against external insults and maintenance of electrolyte homeostasis of the body. Cutaneous
dysfunction can account for the development of both cutaneous and systemic disorders. +us, improvements in cutaneous
functions can benefit a number of extracutaneous and cutaneous functions. Resveratrol, a natural ingredient, displays multiple
benefits for various systems/organs, including the skin. +e benefits of resveratrol for cutaneous functions include stimulation of
keratinocyte differentiation and antimicrobial peptide expression, inhibition of keratinocyte proliferation and cutaneous in-
flammation, UV protection, anticancer, antiaging, and inhibition of melanogenesis. +e mechanisms of action of resveratrol
include activation of sirtuin 1 and nuclear factor erythroid 2-related factor 2, and inhibition of mitogen-activated protein kinase
signaling. Evidence suggests that topical resveratrol could be a valuable alternative not only for daily skin care, but also for the
prevention and treatment of various cutaneous disorders. +is review summarizes the benefits of resveratrol for
cutaneous functions.
1. Introduction
In the traditional view, the skin serves as a protective barrier
between the body and the external environment. Yet, more
and more evidence suggests that cutaneous function extends
far beyond mere protection. In fact, cutaneous function
regulates a wide spectrum of cutaneous and systemic
functions. Compromised epidermal function has been
linked to the development of a variety of cutaneous and
extracutaneous disorders. For example, disruption of epi-
dermal permeability barrier not only provokes the release
and production of proinflammatory cytokines [1–3], but also
induces infiltration and activation of inflammatory cells in
the skin [4–7], suggesting that defective epidermal perme-
ability barrier predisposes to the development of inflam-
matory dermatoses [8–11]. But barrier disruption also
stimulates barrier homeostasis responses, including epi-
dermal proliferation and lipid synthesis [12, 13]. Moreover,
defects in epidermal permeability barrier allow the pene-
tration of microbial pathogens into the skin [14–16].
Importantly, recent studies showed that the epidermal
dysfunction-induced elevations in cutaneous cytokines lead
to increased levels of proinflammatory cytokines not only in
the skin, but also in circulation, supporting not only a
pathogenic role for epidermal function in cutaneous and
extracutaneous inflammation, but also suggesting a link
between cutaneous function and inflammation-associated
systemic disorders [17, 18]. In addition to epidermal per-
meability barrier homeostasis, other epidermal functions,
such as pH and stratum corneum hydration, also regulate
cutaneous functions [19–22]. Accordingly, improvements in
epidermal function could benefit multiple cutaneous and
extracutaneous functions [17, 23–25].
Because of the importance of cutaneous function, much
recent attention has focused on the identification of active
ingredients that could lead to the development of products
that improve cutaneous function. In comparison with
synthetic chemicals, natural ingredients are generally con-
sidered to be cheaper and more widely available, but still
exhibit comparable benefits [26–28]. Among natural
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ingredients, bioflavonoids, including hesperidin, apigenin,
epigallocatechin gallate, and resveratrol, exhibit a wide
spectrum of biological activities, including antioxidative,
anti-inflammatory, anticancer, antiaging, and UV protec-
tion, while improving cutaneous functions. In this article, we
review the current in frontier about the regulatory role of
resveratrol in cutaneous functions.
2. Properties and Sources of Resveratrol
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a stilbenoid,
belonging to a group of phytoalexins, with a molecular
weight of 228.247 g/M and amelting point of 254°C (Figure 1
from http://www.streamstime.com), first identified in 1939
[29]. Resveratrol dissolves well in both ethanol and acetone
(50mg/ml), but barely dissolves in water (3mg/1000ml). It
can be synthesized via Wittig reaction of protected 3,5-
dihydroxybenzaldehyde and methylenetriphenylphosphor-
ane, using reagent aldehyde : sodium hydride : CH3P(C6H5)
Br at a ratio of 1 : 4 : 4 [30, 31] (Figure 2). Yields of resveratrol
can be increased by using unprotected 3,5-dihydrox-
ybenzaldehyde and aldehyde : sodium hydride : CH3P(C6H5)
Br at a ratio of 1 : 4 : 4 [32]. In contrast, the biosynthesis of
resveratrol in plants can begin with acetyl-CoA, tyrosine, or
phenylalanine in response to external stressors, such as
insults from insects, microbial pathogens, animals, or ad-
verse weather conditions [33–35] (Figure 3). Resveratrol
exists as both trans and cis isomers in plants. Trans-
resveratrol can be isomerized to the cis form by UV irra-
diation [36].
Stilbene synthase is a key enzyme in the synthesis of
resveratrol in the plants. Studies demonstrated that both
expression levels of stilbene synthase and resveratrol content
are regulated by a transcription factor, Myb14, which binds
to Box L5 motif, leading to elevated stilbene synthase gene
expression [37]. A number of other factors also regulate
stilbene synthase expression and resveratrol production. For
example, leaves contain the highest level, while the shoot tips
have a relatively low level of stilbene synthase protein and
mRNA in 1-year-old potted grapevines ofVitis vinifera L. cv.
Cabernet Sauvignon [38]. Moreover, during grape devel-
opment, expression levels of stilbene synthase mRNA in-
crease continuously in the grape skin until they became ripe
[39]. Likewise, old leaves of Cabernet Sauvignon exhibit
higher levels of stilbene synthase mRNA than young leaves
[39].
Infections of grapes can also change the expression of
stilbene synthase mRNA. Dai et al. reported that incubation
of cabernet sauvignon leaves with powdery mildew fungal
spores for 24 hours significantly increased expression levels
of stilbene synthase mRNA [39]. Additionally, irradiation of
grape leaves with UVC not only increased the expression
levels of both stilbene synthase protein and mRNA, but also
increased resveratrol content, starting as early as 8 hours
after irradiation [38]. In grape skin, UVB (312 nm) irradi-
ation mainly increased expression levels of stilbene synthase
mRNA in unripe grapes [40]. Wilting grapes at 28°C in-
creased trans-resveratrol content, peaking at day 60, fol-
lowed by a decline [40]. Incubation of grape leaves with
50mM calcium chloride (CaCl2) for 24 hours induced
greater than 2-fold increase in trans-resveratrol content in
comparison with vehicle control [41]. Irradiation with UVC
could further increase trans-resveratrol content in com-
parison with CaCl2 alone [41]. UVC irradiation primarily
increased trans-resveratrol content in young grapes [42].
Seasonal changes in resveratrol content were also observed
in grape roots, with a higher content (103–123mg/kg dry
weight) in the months of May and August to October, and a
lower content (61–93mg/kg dry weight) in the remaining
months of the year [43]. Fungicides and methyl jasmonate
treatments can markedly reduce resveratrol content in
grapes and strawberry, respectively [44, 45]. Taken together,
environmental conditions and the stages of plant develop-
ment affect resveratrol synthesis and content.
Among plants, resveratrol is most abundant in the skin
of red grapes [46]. But some other foods and beverages also
contain fair amounts of resveratrol [34, 47–56]. Moreover, it
appears that the age of the beverage determines its resver-
atrol content. For instance, 15-year-old champagne wine
only contains 1mg/L trans-resveratrol while the same wine,
aged for 8 years, contains 45mg/L trans-resveratrol [53].
Reseveratol
CI4HI2O3
HO
OH
OH
Figure 1: Structure of resveratrol.
Protected 3,5-dihydroxybenzaldehyde Methylenetriphenylphosphorane
Wittig reaction
3,5-dihydroxy-styrene
3,5-diacetoxy-styrene
Acetylation
p-acetoxy-iodobenzene
Heck reaction
Acetylated resveratrol
Resveratrol
Deacetylation 
+
+
Figure 2: Synthesis of resveratrol [30].
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Resveratrol content also varies with different parts of plants.
+e highest content of resveratrol was found in the stem
phloems, but the lowest in the leaves in 1-year-old potted
grapevines [38]. Likewise, resveratrol content in the grape
skin is higher than that in the leaves and seeds for some
grapes [57, 58]. But some grape seeds contain a higher
content of resveratrol than do the skins [58]. Moreover,
resveratrol content varies greatly with cultivars [33, 57–62].
For example, resveratrol content in small white Spanish
peanuts is over 20-fold higher than that in White’s runner
peanuts [33]. Similarly, resveratrol content in the skin of
rootstock grapes is over 100 times that in table grapes [57].
Moreover, resveratrol content in the skin of Berlandier
Resseguier grapes is over 170 times of that in the skin of Dog
Ridge grapes (366 vs. 20 μg/g fresh weight) [57], the same as
in tomatoes, in which the total resveratrol content is 18.4 μg/g
fresh weight in Micro Toms, and 0.34 and 0.38 μg/g fresh
weight, respectively, in Plum Toms and Ugly Ripes [63].+us,
resveratrol content varies with the age of beverage, plant parts,
and the cultivars.
Other factors, such as cultivation sites and nitrogen
availability, can also influence the resveratrol content in
plants [35, 62, 64, 65]. For example, the trans-resveratrol
content in V. vinifera grape cane grown in Yantai is lower
than that grown in Yangling, China (755 vs. 938mg/kg fresh
weight) [62]. Likewise, knotweed from Zunyi, China, con-
tains 4.27± 0.09mg/g of resveratrol. But knotweed from
Yunnan only contains 2.06± 0.03mg/g of resveratrol, while
resveratrol was undetectable in knotweed grown in Dun-
staffnage, Canada [65]. Similarly, the total resveratrol con-
tent is as high as 3.11mg/L in merlot red wines made from
grapes cultivated in Nagano, Japan, while the same wines
only contain 0.88mg/L of total resveratrol, if the grapes are
cultivated in Iwate [35].
Variation of resveratrol content in plants is likely due to
different environment/weather conditions [40–43, 64] and
chemical compositions of soils [45, 66]. In addition, pro-
cessing methods of foods and beverages can affect
resveratrol content. Studies have shown that neither raw nor
dry-roasted peanuts contain detectable trans-resveratrol
[67, 68], but trans-resveratrol content was ≈1.6mg/100g in
boiled peanuts [67] and 10 to 50 μg/100 g in peanut butter
[68]. Moreover, preparation and/or processing methods can
influence resveratrol content in beverages. For example,
ultrasonic cleaning of grapes could increase resveratrol by as
much as over 50% in comparison with that without ultra-
sonic cleaning [69]. Similarly, heating highbush Michigan
blueberries at 190°C for 18min reduced trans-resveratrol by
over 40% as compared to raw blueberries [55]. Moreover,
methanol extraction of grapes yields resveratrol as much as
two times of acetone extraction [70]. In summary, plants and
fruits contain a fair amount of resveratrol. But environ-
mental conditions, developmental stage, and the parts of
plants or fruits largely determine resveratrol content, while
processing methods and storage conditions can affect the
resveratrol content of foods and beverages. +e content of
resveratrol in certain foods, plants, and beverages is sum-
marized in Supplemental Table 1.
3. Benefits of Resveratrol for
Cutaneous Functions
+e benefits of resveratrol for health have been demon-
strated in multiple systems and/or organs, including car-
diovascular system, diabetes, and immune as well as the
neural system [71–76]. A large body of evidence, summa-
rized here, has also indicated the benefits of resveratrol for
the skin (Table 1) [77–126].
3.1. Keratinocyte Proliferation and Differentiation. Both
keratinocyte proliferation and differentiation are required
for the epidermis to reach its ultimate goal of the formation
of the stratum corneum, an essential structure for epidermal
permeability barrier. Several studies have demonstrated that
resveratrol inhibits keratinocyte proliferation while stimu-
lating differentiation. Resveratrol at a concentration as low
as 2 μM markedly inhibits DNA synthesis in keratinocyte
cultures [77]. Inhibitory effect of resveratrol on DNA syn-
thesis occurred as early as 24 hr after addition to cultures,
with an IC50 range of 2–8 μM [77]. Incubation of kerati-
nocytes with resveratrol, at concentrations as low as 0.25 μM
for 72 hr, could induce a dose-dependent reduction in the
number of living cells. Wu et al. reported that 20 μM
resveratrol inhibited keratinocyte proliferation by over 80%,
using the 5-bromo-2-deoxyuridine assay [78]. With long-
term treatments (e.g., two weeks), even 0.197 μM resveratrol
was sufficed to inhibit keratinocyte proliferation by 80%
[82].
+e activities of keratinocyte proliferation and differ-
entiation are coordinated in an inverse manner, while ter-
minal differentiation is crucial for the formation of
permeability barrier. In contrast to proliferation, resveratrol
stimulates keratinocyte differentiation. For example, treat-
ment of keratinocytes with 3 μM resveratrol until 3 days after
postconfluence increased involucrin expression by 1.5-fold
[83]. Moreover, formation of cornified envelopes, critical
Stilbene synthase
Resveratrol
3x Malonyl-CoA 1x Coumaroyl-CoA
Tyrosine Phenyalanine
Cinnamic acid
p-Hydroxycannamic acid
Phenylalanine ammonia-lyase
Cinnamate-4-hydroxylaseTyrosine ammonia-lyase
4-Coenzyme A ligase
Acetyl-CoA
Acetyl-CoA carboxylase 
+
Figure 3: Biosynthesis of natural resveratrol.
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Table 1: Benefits of resveratrol for cutaneous functions.
Models Treatments Benefits Mechanisms Ref.
Keratinocyte
proliferation/
differentiation
Keratinocytes
Cells cultured with 0.25–100 μM
resveratrol for 24–72 hr ↓Proliferation ND [77]
Cells cultured with 20 or 40 μM
resveratrol for 24 hr ↓Proliferation ↑SIRT1 [78]
Cells cultured with 50 μM resveratrol
for 12 hr ↓Proliferation ND [79]
Cells cultured with 25–100 μM
resveratrol for 24 hr ↓Proliferation ND [80, 81]
Cells treated with 0.197 μM resveratrol
for 2 weeks ↓Proliferation ND [82]
Cells cultured with 3 μM resveratrol
until 3 days postconfluence ↓Differentiation ↑SIRT1 [83]
Cells cultured with 100 μM resveratrol
for 24 hr
↓Proliferation↓Differentiation ↓Protein kinase D [84]
Anti-UV
irradiation
Keratinocytes
Immediately after irradiation with
UVA (5 J/cm2), cells were treated with
0.01–0.1mM resveratrol for 24 hr
↑Cell viability↓MDA content ↑SOD and GSH-Pxexpression [85]
Either before or after irradiation with
UVA (2.796 J/cm2), cells were treated
with 2.5 and 5.0mg/l resveratrol,
respectively
↑Cell viability↑SOD and GST ↑NRF2 in nucleartranslocation↓Keap1 [86]
Cells first treated with 10 μM
resveratrol for 1 hr, followed by UVB
irradiation (30mJ/cm2)
↑Cell viability↓Apoptosis ↑Activation of SIRT1 [87]
Cells first treated with 2% of
resveratrol for 2 hr, followed by UVB
irradiation (5–100mJ/cm2)
↑Cell viability ND [88]
Cells treated with 5–25 μM resveratrol
for 24 hr, followed by irradiation with
UVB (40mJ/cm2)
↓NF-κB content and activity ↑IκBα↓IKKα [89]
Cells treated with 5–10 μM
pterostilbene, analog of resveratrol,
for 24 hr, followed by irradiation with
UVB (30mJ/cm2).
↑Cell viability↓ROS↓DNA damage ↑Nrf2 [90]
Cells treated with 50 μM resveratrol
30min prior to irradiation with 1 J/
cm2 UVA +0.1 J/cm2 UVB
↓IL-6, MCP-1, and TNF-α mRNA ↑ARH [91]
Cells treated with 25 or 100 μM
resveratrol for 2 or 24 hr, followed by
irradiation with UVB (10, 20, 40, or
100mJ/cm2)
↑ROS↓Autophagy ↑ERK activation↑Bax/Bcl2 ratio [92]
Cells first irradiated with 1 J/cm2 UVA
+0.1 J/cm2 UVB, followed by
treatment with 10 μM resveratrol.
↓CYP1A1, CYP1B1, IL-1β, IL-6,
and COX2 mRNA levels ↓Peroxide content [93]
Dermal fibroblasts
Immediately after UVB irradiation
(144mJ/cm2), fibroblasts were treated
with 10 or 100 μg/L of resveratrol-
enriched rice extract at various
concentrations for 24–72 hr
↑Cell viability↓ROS↓MMP1, p53, Bax, TNF-α, IL-6,
iNOS, and COX2↑PIP1 and TGF-β protein ND [94]
Reconstructed
human skin
Reconstructed human skin was
treated with 1% of resveratrol-
enriched rice extract for 24 hr,
followed by irradiation with UVB
(100mJ/cm2)
↓MMP1↑PIP1, type I procollagen, and
collagen fibers
ND [94]
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Table 1: Continued.
Models Treatments Benefits Mechanisms Ref.
Mice
Mice were treated topically with
25 μM resveratrol in 200 μl acetone
30min prior to irradiation with
180mJ/cm2 UVB
↓Ear weight and edema↓Inflammatory infiltrate↓ODC activity and COX2 activity↓Lipid peroxidation ND [95]
Mice were treated topically with
10 μM resveratrol in 200 μl acetone
30min prior to irradiation with
180mJ/cm2 UVB
↑Cell proliferation↓COX2 and ODC expression ↓Survivin [96]
Mice were treated topically with 0.48%
resveratrol 20min prior to irradiation
with 360mJ/cm2 UVB
↓Skin edema in mice treated with
resveratrol either before or after
UVB irradiation↓Epidermal thickness in mice
treated with resveratrol before UVB
irradiation
↑NRF2 [97]
Mice were treated topically with 0.48%
resveratrol 20min prior to irradiation
with 180mJ/cm2 UVB, 3 irradiation/
week for a total of 30 weeks
↓Lipid, DNA, and protein
peroxidation↑Activity and expression of
antioxidant enzymes
[97]
Antioxidant defense
Keratinocytes
Cells cultured with 20 and 60 μM
resveratrol for 24 hr ↑GST activity ↑NRF2 expression andactivation [98]
Cells pretreated with 10 or 20 μM
resveratrol for 16 hr
↑NQO1 and GSH-Px mRNA↑GSH protein synthesis ↑NRF2 activation [99]
Cells treated with both 0.3–3mM
sodium nitroprusside and 1–30 μM
resveratrol for 24 hr
↑Cell viability↓Caspase 3 and 9 activity ↓IL-8, NOS3, and NADPHdehydrogenase mRNA↑GSH-Px mRNA [100]
Cells pretreated with 25 or 100 μM
resveratrol 24 hr prior to addition of
200, 400, or 800 μM H2O2 and cells
were harvested 48 hr postaddition of
H2O2
↓ROS ND [92]
Cells pretreated with 140 μM
resveratrol for 1 h, then 500 μM H2O2
was added, and incubated for
additional 2–16 h
↓DNA damage and HSP70
expression ND [101]
Cells treated with 10 μM resveratrol
for 24 hr, and then 100 μM H2O2 was
added and incubated for additional
30min
↓ROS↓MDA ND [102]
Cells pretreated with 0.5–10 μM
resveratrol for 24 hr, followed by
removal of media, and then exposed to
cigarette smoking for 50min
↑Scavenger receptor class B type I
protein and mRNA↓4-Hydroxynonenal adducts ND [103]
Cells pretreated with 10 μM
resveratrol for 24 hr, followed by
removal of media, and then exposed to
cigarette smoking for 50min
↓ROS and carbonyl groups ↑Methionine sulfoxidereductase A mRNA↓Transient receptor potentialcation channel subfamily A
member 1 mRNA and
protein
[104]
Cells pretreated with 0.5 μM
resveratrol for 3 hr, followed by
addition of 0.1–20 μM arsenic and
incubation for additional 20 hr
↓Arsenic-induced increase in
metabolic activity and expression of
DNA polymerase beta↑Arsenic-induced reduction in
Y419 phosphorylation and Src
protein
ND [105]
Reconstructed
human skin
Keratinocytes were pretreated with 20
or 100 μM resveratrol for 16 hr,
followed by removal of media, and
then exposed to 800 μM cumen
hydroperoxide for 8 hr
↑GSH expression↓Apoptosis ↑NRF2 activation [99]
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Table 1: Continued.
Models Treatments Benefits Mechanisms Ref.
Mice
Mice were treated topically with
16 μM resveratrol, and four hours
later, skin samples were collected
↑GST activity and content ↑NRF2 activation [98]
Mice were treated topically with 8 or
16 μM resveratrol, and twenty-four
hours later, skin samples were
collected
↑Glucuronosyltransferase and
NADPH:quinone oxidoreductase
activity
ND [106]
Humans
Stratum corneum was collected with
tape strip 24 hr after single application
of resveratrol at a dose of 537 μg/cm2
on the ventral forearm
↓Production of free radical ND [107]
Anticancer
Melanoma cell line Cells were treated with 20–40 μg/mlresveratrol for up to 5 days
↓Proliferation↓Apoptosis and necrosis ↑Cells in S phase arrest↓Cells in G1 and G2/M phase [108]
A431 human skin
carcinoma cells
A431 cells were treated with
20–100mg/L resveratrol for 24 hr
↑Apoptosis↓Proliferation ↑Activation of MAPKpathway [81]
A431 cells were treated with 20, 50,
and 100 μM resveratrol for up to 72 hr
↓DNA synthesis and proliferation↓Cells in G2/M phase↓Cell cycle regulatory proteins ↓DNA-binding activity ofAP-1↓ERK1/2 signaling pathway [109]
Human squamous
cell carcinoma cell
lines
HSC2 cells were treated with both
resveratrol and benzoxazinotropone
at various concentrations for 48 hr
Resveratrol and
benzoxazinotropone synergistically
inhibited proliferation
ND [110]
Head and neck
squamous cell
carcinoma cells
Head and neck squamous cell
carcinoma cells were treated with 15
and 50 μM resveratrol for up to 72 hr
↓Proliferation↑Apoptosis ↑H2AX ser-139phosphorylation [111]
Mice
Mice with squamous cell tumor graft
were gavaged orally with 10 and
50mg/kg body weight of resveratrol
for 30 days
↓Tumor weight and volume per
mouse
Anti-inflammation
Keratinocytes
Cells treated with 20 ng/ml TNF-α for
6 hr 10 μM, followed by incubation
with resveratrol for additional 16 hr
↓IL-6 and MCP-1 ↓Phosphorylation of IκBα [102]
Cells treated with 7.5 μg/mL
lipopolysaccharide for 12 hr, followed
by incubation with 10–50 μM
resveratrol for additional 12 hr
↑Proliferation↑Apoptosis↓IL-6, IL-8, and TNF-α mRNA and
protein
↑miR-17 expression [112]
Cells treated with 50 μM resveratrol
1 hr prior to addition of 2.5 μg/mL
lipopolysaccharide
↓IL-6, IL-8, MCP-1, and COX2
mRNA
↓EGFR-ERK signaling
pathway [91]
Cells pretreated with 25 and 50 μM
resveratrol for 30min, followed by
incubation with 25 μg/ml cetuximab
or 2 μM gefitinib for additional 3 hr
↓CCL2 and CXCL10 mRNA and
protein
↓Interferon regulatory factor
1 and phosphorylated STAT1 [113]
Cells pretreated with 50 μM
resveratrol for 1 hr, followed by
incubation with for 10 ng/ml IFN-c
and TNF-α 24 hr
↓IL-6 ND [114]
Cells pretreated with 44 μM
resveratrol for 24 hr, followed by
exposure to heat stress for 40min
↓IL-6, IL-8, and TNF-α ND [115]
Mast cells
RBL-2H3 mast cells were pretreated
with 1–25 μM resveratrol for 2 hr,
followed by exposure to 200 ng/ml
dinitrophenyl-human serum albumin
↓IL-3, IL-4, IL-13, and TNF-α↓Fc epsilon receptor I expression ↓P38-MAPK, ERK1/2, JNK [116]
Reconstructed
human skin
3D skin was treated 10 ng/ml IFN-c
and TNF-α twice a week, followed by
treatment with 1% resveratrol thrice
weekly for 2 weeks
↓IL-6 ND [114]
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Table 1: Continued.
Models Treatments Benefits Mechanisms Ref.
Mice
BALB/c mouse ears were treated
topically with 10mM resveratrol 2 hr
prior to DNFB challenge
↓Ear thickness↓CD3-positive cells↓ICAM-1, CCL2, and CXCL10
expression
↓Interferon regulatory factor
1 and phosphorylated STAT1 [113]
Following induction of allergic
contact dermatitis, NC/Nga mice were
treated topically with 2.5% resveratrol
or resveratrol-enriched rice extract
twice weekly for 5 weeks
↓Epidermal thickness↓Dermatitis score↓Serum IgE↓TEWL↑Skin hydration ND [114]
BALB/c mice were orally treated with
resveratrol at a dose of 10mg/kg body
weight 1 hr prior to intravenous
challenge with 200 μg dinitrophenyl-
human serum albumin
↓IL-4 and TNF-α↓CD11b-positive cells ↓Tyk2-STAT1 activation [116]
Atopic dermatitis-like lesions were
induced by topical applications of
DNFB to the back of BALB/c mice for
5 weeks, followed by orally given
resveratrol at a daily dose of 30mg/kg
body weight for 1 week
↓Dermatitis scores↓Epidermal thickness↓Cytokine mRNA ND [117]
Atopic dermatitis-like lesions were
induced by topical applications of
dermatophagoides farinae to the back
of NC/Nga mice for 2weeks, followed
by orally given resveratrol at a daily
dose of 20mg/kg body weight for 2
weeks
↓Dermatitis scores↓Cytokine mRNA and protein ↓High mobility group box 1expression [118]
Psoriasis-like skin lesions were
induced by topical applications of
imiquimod to the back of BALB/c
mice, which were orally given
resveratrol at a daily dose of 400mg/
kg body weight, for 7 days.
↓Erythema and scale scores↓Skin thickness↓Cytokine mRNA ND [119]
Accelerating wound
healing
Rats
Rats were fed with resveratrol at a
daily dose of 0.5mg/kg body weight 7
days prior to operation and continued
throughout the whole experiment
period
↑Collagen deposition↑Neovascularization↑Fibroblast maturation ND [120]
Following induction of full-thickness
skin wound, wound was treated
topically with 225 μL of 50 μM once
daily for 17 days
↑Epithelialization↓Wound size↑Collagen deposition↑Vascularization ↑AMPK pathway and SIRT1 [121]
Mice
Immediately after wound, a wound
dressing containing 0.04% resveratrol
was applied to full-thickness skin
wound for 10 days
↓Wound size↑Collagen fibers↓Inflammation ND [122]
Placing scaffolds containing 5%
resveratrol on the wound for 7 days ↓Wound size ↑Expression of thioredoxin-1, heme oxygenase-1, andVEGF [123]
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structures for epidermal permeability barrier, requires
transglutaminase [127]. Treatment of keratinocytes with
resveratrol induced a dose-dependent increase in trans-
glutaminase activity, while simultaneously inhibiting DNA
synthesis, with a half-maximal concentration of 35 μM.
Finally, resveratrol and 1, 25(OH)2D3 synergistically in-
creased transglutaminase activity [84]. +us, resveratrol
inhibits keratinocyte proliferation, while stimulating
differentiation.
3.2. Anti-UV Irradiation. While suberythemogenic doses of
UVB irradiation instead enhance epidermal function, in-
cluding improvements in epidermal permeability barrier
function, stimulation of epidermal lipid synthesis and kera-
tinocyte differentiation, and antimicrobial defense [128],
excessive exposure to UV irradiation can damage the skin,
causing sunburns, skin cancers, and photoaging. Both in vivo
and in vitro studies have demonstrated that resveratrol
protected the skin fromUV irradiation. For example, addition
of 0.1 μM resveratrol to the culture medium immediately
postirradiation provided 100% protection against UVA-
induced reductions in keratinocyte proliferation and an in-
crease in malondialdehyde (MDA) content. In parallel, both
superoxide dismutase (SOD) and glutathione peroxidase
(GSH-Px) contents in UVA-irradiated keratinocytes were
normalized by treatment with resveratrol [85]. Either prior to
or post-UVA irradiation, treatment of keratinocytes with
resveratrol decreased lipid peroxidation. But only pretreat-
ment, not posttreatment with resveratrol, increased SOD and
glutathione S-transferase (GST) protein levels [86]. In addi-
tion to UVA irradiation, resveratrol can also protect kerati-
nocytes from UVB-induced damages. For example, treatment
of keratinocytes with resveratrol 1 hr prior to UVB irradiation
decreased apoptosis rates by over 50% [87]. Moreover,
treatment of keratinocytes with resveratrol prior to UV ir-
radiation decreased the expression levels of proinflammatory
cytokines, such as IL-6, IL-8, and TNF-α, by ≈50% from
untreated keratinocytes [91]. Likewise, addition of 10 μM
resveratrol immediately after UVA and UVB irradiation also
lowered the expression levels of IL-1-beta and IL-6 [93]. In
addition, treatment of dermal fibroblasts with resveratrol after
UVB irradiation decreased the contents of (i) reactive oxygen
species, (ii) TNF-α and IL-6, (iii) inducible nitric oxide
synthase (iNOS), and (iv) expression levels of matrix met-
allopeptidase I, while increasing procollagen 1 and elastin
[94]. It appeared that pretreatment of keratinocytes with low
concentration of resveratrol did not inhibit UV irradiation-
induced inflammation [93].
+e protective effects of resveratrol against UV irradi-
ation have also been demonstrated in vivo. Afag et al. re-
ported that topical application of 25 μM resveratrol 30min
prior to UVB irradiation (180mJ/cm2) decreased skin
thickness and punch weight of ear by over 50 and 81%,
respectively, in comparison with vehicle-treated controls
[95]. Moreover, cutaneous inflammatory infiltration and
ornithine decarboxylase protein levels decreased signifi-
cantly in mouse skin treated with topical resveratrol prior to
UVB irradiation [96]. Yet, topical applications of resveratrol
post-UVB irradiation decreased whole skin thickness, but
not epidermal thickness [97]. Some studies showed that
resveratrol and UV irradiation synergistically enhanced
expression levels of IL-8 mRNA and protein, and DNA
damage in keratinocytes as compared to UV irradiation
alone [129, 130]. +ese discrepant results could be attrib-
utable to variations, including the doses of resveratrol and
UV irradiation, treatment timing, and/or the status of
growth and differentiation in these cells. +us, further
studies are needed to clarify the effects of resveratrol on
cutaneous function.
3.3. Antioxidant Defense. A number of factors, including
psychological stress, cigarette smoke, air pollution, and UV
irradiation, can cause oxidative stress, contributing to the
development of aging and a line of disorders such as der-
matoses, inflammation, cardiovascular diseases, cancer, and
neurodegenerative diseases [131–139]. Accordingly,
Table 1: Continued.
Models Treatments Benefits Mechanisms Ref.
Diabetic models
0.5% resveratrol ointment was applied
to wound area in diabetic rats once
daily for 21 days
↓Wound size ↑Activity of antioxidantenzymes [124]
10 μM resveratrol was applied to the
cutaneous wound area in diabetic
mice, and wound healing was assessed
7 days later
↓Wound size↑Endothelial cell proliferation Sirt1 activation [125]
Fourteen days after topical application
of resveratrol (0.1mg/ml) to wound
area in diabetic rats once, wound
healing was assessed
No benefit [126]
Abbreviations: ND, not determined; AQP3, aquaporin 3; SOD, superoxide dismutase; MDA, malondialdehyde; GSH-Px, glutathione peroxidase; GST,
glutathione S-transferase; GSH, reduced glutathione; NQO, NAD(P)H:quinone oxidoreductase; ROS: reactive oxygen species; CYP1A1, cytochrome P540
family 1 subfamily A member 1; IKKα, ΙκB kinase α; CYP1B1, cytochrome P540 family 1 subfamily B member 1; COX, cyclooxygenase; ODC, ornithine
decarboxylase; NRF2, nuclear factor erythroid 2-related factor 2; ERK: extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; JNK, c-
Jun NH2-terminal kinase; TPA, 12-O-tetradecanoyl13-phorbol acetate; DNFB, 2,4-dinitro-1-fluorobenzene; NOS, nitric oxide synthase; VEGF, vascular
endothelial growth factor; AMPK, adenosine monophosphate-activated protein kinase.
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antioxidants have been utilized to prevent and treat certain
disorders [140–142]. Among the antioxidants, benefits of
resveratrol have also been studied extensively both in vitro
and in vivo. Phase II enzymes, including GSH-Px, quinone
dehydrogenase (NQO), GST, SOD, and GSH, are respon-
sible for antioxidation in living organisms. Soeur et al. re-
ported that 10 μM resveratrol induced an over 2-fold
increase in expression levels of mRNA for GSH-Px and
NQO1, along with over 1-fold increase in glutathione
synthesis, in keratinocytes, in addition to an over 7-fold
increase in expression levels of mRNA for GSH-Px and
NQO1 in reconstructed human skin [99]. Resveratrol can
also protect keratinocytes from damages caused by oxidative
stressors, including nitric oxide (NO), H2O2, cigarette
smoke, and arsenic [92, 101–105]. Surprisingly, topical
resveratrol did not mitigate UVB irradiation-induced re-
ductions in both activity and expression levels of antioxidant
enzymes, including catalase, SOD, and GSH-Px, in a mouse
model of chronic UVB irradiation [97]. NO is a free radical
required for maintenance of normal function, but excessive
NO can induce oxidative stress, leading to apoptosis [136].
Topical applications of human skin with NO donor (nitrite)
caused cutaneous inflammation and keratinocyte apoptosis
[137]. Likewise, 3mM sodium nitroprusside induced ≈70%
inhibition of keratinocyte proliferation [100]. Treatment of
keratinocytes with the combination of 30 μM resveratrol and
3mM sodium nitroprusside reduced caspase 3 and 9 activity
as well as apoptotic rate by 80% from cultures treated with
sodium nitroprusside alone. H2O2 is commonly used as
stressor to induce oxidative stress. Following the treatment
of keratinocytes with 400 μM H2O2, reactive oxygen species
(ROS) content increased 1.5-fold over the controls [92].
Resveratrol at concentrations of 25 μM and 100 μM lowered
ROS contents by 25% and 40%, respectively, in comparison
with cells treated with H2O2 alone. Finally, the protective
effects of resveratrol against oxidative stress have also been
demonstrated in keratinocytes treated with either arsenic or
cigarette smoke [103–105].
+e skin, an interface between the body and external
environment, is vulnerable to environmental insults, in-
cluding oxidative stress, leading to acceleration of skin aging
and the development of a variety of skin disorders
[138, 139, 143]. +erefore, enhancement of antioxidant
defense of the skin could help manage various cutaneous
dermatoses. Krajka-Kuz´niak et al. showed that a single
topical treatment of mouse skin with 16 μM resveratrol for
4 hr increased GST activity by 63% and GST content by 22%
over controls [98]. Similarly, a greater than 1-fold increase in
GST activity was observed in mouse epidermis 24 hr after
topical application of 16 μM resveratrol [106]. Likewise,
production of free radicals was reduced in human stratum
corneum following topical treatment with resveratrol for
24 hr [107]. Collectively, resveratrol exhibits antioxidant
properties both in vitro and in vivo.
3.4. Anticancer. Oxidative stress has been considered as a
major contributor to the development of skin cancers, such
as melanoma [144–146]. Accordingly, antioxidants,
including resveratrol, have been used to prevent and treat
skin cancer [147–149], although exacerbation and increased
risk of cancers have been reported [150, 151]. Melanoma is
the most serious type of skin cancer, with mortality rates of
3.1/100,000 in the US [152] and 1.4–1.9/100,000 in Germany
[153]. Antimelanoma benefits of resveratrol have been
demonstrated both in vivo and in vitro. Studies in melanoma
cell cultures showed that resveratrol inhibited proliferation
of melanoma cells, with a concentration of 7 μg/ml inducing
a 50% inhibition of cell growth [108]. It seems that mela-
noma cells are more sensitive to resveratrol than kerati-
nocytes, which instead required a concentration of 20 μg/ml
to cause 50% inhibition of cell growth. Moreover, resveratrol
dose-dependently increased both apoptotic and necrotic
cells after 24 hr treatment of two melanoma cell lines [108].
In addition, resveratrol also inhibited the growth of squa-
mous cell carcinoma cells (A431 cell line) [81]. Resveratrol-
induced apoptosis and inhibition of cell proliferation were
also observed in human head and neck squamous cell
carcinoma cell lines, e.g., FaDu, Cal27, and Det562 cell lines
[111]. Moreover, rates of DNA synthesis were reduced by
78% following the treatment of carcinoma cells with 25 μM
resveratrol for 72 hr [109]. In vivo studies showed that oral
administration of resveratrol resulted in a dose- and time-
dependent inhibition of carcinoma cell growth, with over
50% reductions in both tumor volume and weight per mouse
following 30-day treatment with resveratrol at a dose of
50mg/kg body weight [111]. Taken together, resveratrol
demonstrates potential anticancer activity both in vivo and
in vitro.
3.5. Anti-Inflammation. Inflammatory dermatoses prove
the most common clinical problems in dermatology. Be-
cause of the severe side effects of immune modulators, such
as glucocorticoids and tacrolimus, safe and effective alter-
natives are highly demanded. Studies have shown that
resveratrol is safe in both animals and humans [154, 155],
but it can effectively inhibit inflammation both in vitro and
in vivo. For example, incubation of keratinocytes with 50 μM
resveratrol for 3 hr lowered the expression levels of mRNA
for IL-6, IL-8, TNF-α, and macrophage inflammatory
protein 1 (MIF-1) by over 50% [91]. While production of
proinflammatory cytokines markedly increased in kerati-
nocytes exposed to TNF-α, lipopolysaccharide, interferon c
(IFN-c), and UV irradiation [91, 102, 112–114], addition of
50 μM resveratrol 1 hr prior to lipopolysaccharide treatment
dramatically decreased mRNA levels (>40% reduction) for
MIF-1, IL-6, and cyclooxygenase 2 in comparison with
keratinocytes treated with lipopolysaccharide alone [91].
Yet, resveratrol also dose-dependently stimulated IL-8
production in keratinocyte cultures [91], suggesting that
resveratrol differentially regulates cytokine production.
Although there is still little or no evidence that resveratrol
can inhibit cutaneous inflammation in humans, anti-in-
flammatory benefits of resveratrol have been well demon-
strated in murine models of inflammatory dermatoses. For
example, in acute allergic contact dermatitis model, pre-
treatment of mouse ears with resveratrol reduced the density
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of CD3+ cells by≈90% in parallel with significant reduction of
ear thickness and expression levels of intercellular adhesion
molecule 1 (ICAM-1), C-X-C motif chemokine ligand 10
(CXCL10), C-Cmotif chemokine ligand 2 (CCL2), and IFN-κ
in the epidermis [113], suggesting preventive benefits of
topical resveratrol in acute allergic contact dermatitis.
Moreover, the therapeutic effects of topical resveratrol have
also been demonstrated in an atopic dermatitis-like disease
model. Kang et al. showed that topical applications of either
2.5% resveratrol or resveratrol-enriched rice extract for five
weeks markedly reduced dermatitis score and serum IgE
levels in a dermatitis model induced by topical dinitro-
chlorobenzene [114]. Likewise, both intravenously and orally
given resveratrol significantly alleviated dermatitis score and
decreased cytokine expression [117, 118].
Psoriasis is another common, inflammatory skin disorder.
Kjaer et al. showed that oral administrations of trans-
resveratrol at a daily dose of 400mg/kg body weight induced
over 50% reductions in both erythema and scale scores, along
with 15% decrease in skinfold thickness of the back skin, in an
imiquimod-induced psoriasis-like mouse model [119]. In
addition, topical resveratrol also decreased the expression
levels of IL-17a and IL-19 mRNA by ≈60% in comparison
with mice treated with imiquimod alone [119]. Together,
these results show that both topical and systemic adminis-
tration of resveratrol can mitigate cutaneous inflammation.
3.6. Cutaneous Wounding. Cutaneous wound healing in-
volves the proliferation of both fibroblast and keratinocytes,
as well as collagen deposition. A number of observations
suggested that, in murine models of full-thickness wound,
resveratrol stimulates cell proliferation and collagen, leading
to acceleration in cutaneous wound healing. Application of
wound dressings containing resveratrol to full-thickness
skin wounds induced marked reductions in wound areas in
comparison with the controls [122]. Similar acceleration in
wound closure occurs following the placement of scaffolds
containing resveratrol over the wound [123]. +is evidence
indicates that topical resveratrol accelerates wound healing
in normal mice.
Management of slow wound healing in diabetics has been
a substantial challenge. Yes, studies have shown that either
topical or systemic administrations of resveratrol can improve
cutaneous wound healing in animal model of diabetes.
Moreover, the efficacy of topical resveratrol ointment for
wound healing was superior to that of topical β-sitosterol,
conventional wound healing product [124]. Huang et al. also
reported that a single application of resveratrol accelerated
cutaneous wound healing in diabetic mice [125]. However,
other studies have shown little or no benefit of resveratrol in
wound healing following a single application in diabetic rats
[126]. +us, the potential benefits of resveratrol for wound
healing in diabetic models still need to be validated.
3.7. Others. Studies in both humans and murine models
reveal that resveratrol also regulates other cutaneous
functions, including skin aging, melanogenesis, and anti-
microbial defense. In human keratinocyte cultures,
resveratrol reduced 90% reduction in expression levels of
beta-galactosidase, a biomarker of senescence, in an aging
model induced by oxidative stress [156, 157]. Clinical trials
have also demonstrated the antiaging properties of resver-
atrol. A study in 50 humans with clinical signs of aging
showed that oral fruit extracts that contain resveratrol
markedly improved multiple aging-associated parameters,
including increased stratum corneum hydration and skin
elasticity, decreased skin roughness and wrinkle depth, as
well as reductions in the intensity of pigmented solar len-
tigines [158]. In parallel, levels of plasma derivatives of ROS
dramatically declined, while skin ferric-reducing ability
increased. In addition, topical applications of resveratrol-
containing products also improved aging-associated signs,
such as skin wrinkles, stratum corneum hydration, and
pigmentation, in aged humans [159]. But in one clinical trial
in 30 subjects, oral supplement of product containing trans-
resveratrol did not appreciably improve skin aging, despite
reductions in cutaneous MDA content and elevations in
SOD content [160]. +ese discrepant results suggest that
additional trials are still needed to determine whether
resveratrol benefits skin aging.
Other studies suggest that resveratrol exhibits antimi-
crobial properties. Cathelicidin antimicrobial peptides
(CAMP) are a family of polypeptides, produced by kerati-
nocytes, macrophages, and polymorphonuclear leukocytes,
that display antibacterial, antifungal, and antiviral activities.
Park et al. reported that incubation of keratinocytes with
resveratrol for 24 hours increased the expression level of
CAMP mRNA by over 4-fold [161]. But resveratrol may also
directly inhibit microbial growth because incubation with
resveratrol induced time- and dose-dependent reductions in
Propionibacterium acnes colony-forming units, possibly due
to disruption of the bacterial membrane [162]. Studies have
shown that resveratrol exhibits several bactericidal and
bacteriostatic activity against several pathogens, including S.
pyogenes, S. aureus, C. glabrata, and C. albicans, with
minimum inhibitory concentrations as low as 1.25mg/ml
[163]. Moreover, topical applications of 25% resveratrol
cream markedly decreased lesion scores for herpes simplex
infection, with an efficacy comparable to 5% acyclovir
ointment, in a mouse model of herpes simplex infections
[164]. Similar results were also obtained with topical ap-
plications of oxyresveratrol in mice infected by herpes
simplex virus [165, 166]. Furthermore, studies also suggest
benefits of resveratrol for keloids. For example, resveratrol
induced apoptosis of fibroblasts from keloids, in parallel
with reductions in the expression levels of mRNA for col-
lagen 1 and procollagen 3, while increasing expression of
SIRT1, suggesting a potential application of resveratrol for
the treatment of keloids and hypertrophic scars [167–169].
Other studies have demonstrated that topical resveratrol
improves epidermal permeability barrier function and
stratum corneum hydration in sodium dodecyl sulfate-
damaged human skin [170]. Additionally, both in vitro and
in vivo studies have shown that resveratrol reduces skin
pigmentation via inhibition of tyrosinase activity, cytokine
production, and melanocytic microphthalmia-associated
transcription factor (MITF) expression [171]. Yet, all of these
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putative benefits of resveratrol for cutaneous function still
lack sufficient clinical validation. +erefore, well-designed
clinical trials are still required before resveratrol can be
widely utilized in clinical settings.
4. Mechanisms of Action
Evidence of resveratrol for multiple cutaneous functions has
been well demonstrated, but the underlying mechanisms
whereby resveratrol acts remain unclear. A line of evidence
suggests that the actions of resveratrol could be via multiple
mechanisms such as upregulation of nuclear factor erythroid
2-related factor 2 (Nrf2), activation of sirtuin 1 (SIRT1), and
mitogen-activated protein kinase (MAPK) signaling path-
way, depending on which function is regulated. +e major
putative mechanisms by which resveratrol regulates cuta-
neous function are illustrated in Figure 4.
4.1. Keratinocyte Proliferation and Differentiation.
Keratinocyte proliferation and differentiation, which are
inversely regulated, are both required to form the stratum
corneum, the outmost layers of the skin, providing multiple
cutaneous protective functions because resveratrol can
stimulate keratinocyte differentiation while inhibiting pro-
liferation, resulting in acceleration of epidermal maturation.
+e inhibitory effects of resveratrol on keratinocyte prolif-
eration occur via two mechanisms: (i) activation/upregu-
lation of SIRT1 and (ii) inhibition of protein kinase D. In
keratinocyte cultures, resveratrol upregulated expression of
SIRT1, leading to elevation in aryl hydrocarbon receptor
nuclear translocator (ARNT), resulting in downregulation of
aquaporin 3, and consequently inhibiting cell proliferation
[78]. Lee et al. showed that resveratrol increased the ex-
pression level and deacetylase activity of SIRT1, resulting in
apoptosis [172]. Other studies suggest that resveratrol in-
hibits DNA synthesis, while increasing transglutaminase
activity via inhibition of protein kinase D activity [84].
Moreover, activation of SIRT1 by resveratrol could also
increase keratinocyte differentiation [83]. Activation of
SIRT1 by resveratrol is likely via enhancement of the binding
of specific substrates to SIRT1 [173]. +us, resveratrol could
inhibit keratinocyte proliferation and stimulate differenti-
ation via both activation of SIRT1 and/or inhibition of
protein kinase D.
4.2. Protection fromUV Irradiation and Antioxidant Defense.
Although the precise mechanisms by which resveratrol
protects the skin against UV irradiation and oxidative stress
are unclear, a handful of evidence points to a central role of
Nrf2. +is transcription factor regulates phase 2 antioxidant
enzymes, which protect against UV irradiation- and other
oxidative stress-induced damage to the skin. Nrf2 deficiency
accelerated UV irradiation-induced photoaging and in-
flammation [174, 175], while conversely activation of Nrf2
protects against UV irradiation-induced apoptosis and in-
flammation [176, 177]. Normally, Nrf2 together with Kelch
ECH associating protein 1 (Keap1) forms a complex, which
is degraded by the ubiquitin-proteasome system [178]. Upon
oxidative stress (including UV irradiation-induced oxidative
stress), Nrf2 is released from Nrf2/Keap1 complex and
translocates into the nucleus, where Nrf2 binds to antiox-
idant response element (ARE) in a heterodimeric complex,
consequently leading to increased production of phase 2
antioxidant enzymes. While UV irradiation can increase the
production of reactive oxygen species and oxidative prod-
ucts [179, 180], resveratrol can attenuate UV-induced oxi-
dative stress via upregulation and/or activation of Nrf2. For
example, treatment of keratinocytes with resveratrol either
before or after UVA irradiation induced >50% increase in
Nrf2 content, while increasing content of Nrf2 in the nuclear
fraction [86, 90]. Similarly, treatment of either normal mice
or oxidative-stressed keratinocytes with resveratrol increases
Nrf2 expression and activation [98, 99], leading to increased
expression of phase 2 antioxidant enzymes and reductions in
reactive oxygen species [85, 90, 100], ultimately protecting/
alleviating cell damage induced by UV irradiation or other
oxidative stressors.
With regard to how resveratrol upregulates Nrf2 ex-
pression and activity, at least three mechanisms probably are
operative. One mechanism involves upregulation of SIRT1
expression. Resveratrol is a SIRT1 activator [83]. Treatment
of adipocytes with resveratrol significantly increased ex-
pression levels of SIRT1mRNA [181]. Upregulation of SIRT1
expressions, in turn, increases expression levels of Nrf2 and
phase 2 antioxidant enzymes, while silencing SIRT1 with
siRNA decreases Nrf2 protein as well as activity of ARE
promotor [182]. Moreover, upregulation and activation of
Nrf2 expression by SIRT1 were also observed [183]. +e
second mechanism comprises direct upregulation of Nrf2
expression because studies have shown that resveratrol in-
creases Nrf2 expression in kidney, heart, and lung tissues
[184, 185]. +e third mechanism is direct downregulation of
Keap1 expression. Treatment of keratinocytes with resver-
atrol either before or post-UVA irradiation lowers expres-
sion levels of Keap1 protein [86]. Resveratrol-induced
reduction of Keap1 expression was also observed in the
kidney and lung tissues of obese and asthmatic rats [185].
Reductions in Keap1 expression can slow Nrf2 degradation,
resulting in an increase in Nrf2 expression. Other studies
also showed that resveratrol stimulated Nrf2 expression and
nuclear translocation without changing the expression levels
of Keap1 [98, 184]. Interestingly, Nrf2 and SIRT1 can
positively coregulate each other. For example, treatments of
either renal tubular cells or glomerular mesangial cells with
resveratrol parallelly increased Nrf2 and SIRT1 expression.
Knockdown of Nrf2 with siRNA decreases the expression
levels of SIRT1, and vice versa [184, 186]. +erefore,
resveratrol can sequentially or separately upregulate SIRT1
and Nrf2, while downregulation of Keap1 expression,
resulting in increased expression of phase 2 antioxidant
enzymes, which in turn protect the skin from UV irradia-
tion- and oxidative stress-induced damage. Finally, one
study showed that inhibition of phosphatidylinositol-3-ki-
nase prevented the activation of Nrf2 induced by pter-
ostilbene, a resveratrol analog, suggesting that resveratrol
can also activate Nrf2 via activation of phosphatidylinositol-
3-kinase [90].
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Still other mechanisms could also account for the actions
of anti-UV irradiation and antioxidative stress. For example,
pretreatment of keratinocytes with resveratrol almost
completely prevents the activation of NFκB induced by UVB
irradiation [89], suggesting that resveratrol-induced inhi-
bition of NFκB activation could contribute to its anti-UV
irradiation properties. Resveratrol-induced upregulation of
heat-shock protein 27 (HSP27) and downregulation of
caspase 3 could also contribute to its anti-UV irradiation
property [187]. +us, resveratrol protects skin against UV
irradiation and oxidative stress via multiple mechanisms.
4.3. Anticancer Activity. Both in vitro and in vivo studies
have shown that resveratrol also inhibits proliferation, while
stimulating apoptosis of cancer cells via several mechanisms.
First, resveratrol induces apoptosis and phosphorylation of
MAPK/ERK and MAPK/p38 in addition to increasing ex-
pression levels of caspase 3 and p53, while conversely, in-
hibition of p38 abolished its apoptotic effects [81, 188]. It
appears that resveratrol-induced phosphorylation of p53
and apoptosis is mediated by c-Jun NH2-terminal kinases
because knockdown of c-Jun NH2-terminal kinase genes
prevented both phosphorylation of p53 and apoptosis in-
duced by resveratrol [189]. +erefore, resveratrol-induced
activation of the MAPK/p38 signaling pathway likely ac-
counts, at least in part, for its anticancer effects. Regarding
antiproliferation of cancer cells, resveratrol inhibits ex-
pression of MEK1-P and ERK1/2-P, leading to reductions in
cyclin D1 and cyclin-dependent kinase 6 expression,
resulting in cell cycle at rest [109]. Moreover, resveratrol also
decreased c-Jun levels and reduced DNA-binding and
transcriptional activity of activator protein-1, which is re-
quired for initiation of DNA synthesis [190]. Other studies
showed that inhibition of NF-κB, cyclooxygenase 2, phos-
phatidylinositol-3-kinase, and P450 isoenzyme CYP1A1 and
induction of caspases 3 and 9 also could contribute to an-
ticancer effects of resveratrol [191–196]. +us, resveratrol-
induced reductions in expression levels of MEK1-P and
ERK1/2-P and decreased activator protein-1 activity could
contribute to its inhibition of cancer cell proliferation.
4.4. Anti-Inflammatory Activity. +e anti-inflammatory
effects of resveratrol have been demonstrated in various in
vivo and in vitro models, but the mechanisms of the ac-
tions of resveratrol are often unclear, depending on the
inflammatory models employed in the studies. One
possible mechanism is inhibition of NF-κB signaling
pathways. Activation of NF-κB can upregulate tran-
scription of cytokines while IκB inhibits NF-κB activity
[102, 197]. Hence, degradation of phosphorylated IκB
would increase NF-κB activity. Resveratrol-containing
mixture inhibited IκB phosphorylation and decreased NF-
κB, resulting in reductions in cytokine production in
keratinocytes stimulated by TNF-α [102]. Another study
suggests that inhibition of cytokine production by
resveratrol seems linked to upregulation of miR-17 ex-
pression in keratinocytes stimulated with lipopolysac-
charide because inhibition of miR-17 overcame the
inhibitory effects of resveratrol on inflammation [112].
But one study showed that resveratrol increases IL-8
production in keratinocytes stimulated with a combina-
tion of TNF-α and IFNc via upregulation of aryl hy-
drocarbon receptor expression [91]. Inhibition of allergic
contact dermatitis by resveratrol could be attributable to
the downregulation of interferon regulatory factor 1/
STAT1 signaling pathway and inhibition of phosphory-
lation of MAPK/p38 and/or phospholipase Cc
[113, 116, 198]. Moreover, resveratrol inhibited prolif-
eration and differentiation of CD+ T cells and prolifer-
ation of +17 T cells via upregulation of phosphorylated
MAPK and downregulation of phosphorylated mamma-
lian target of rapamycin (p-mTOR) in Jurkat cells [199].
Furthermore, resveratrol-induced inhibition of TNF-
α-induced cytokine production in fibroblasts is via acti-
vation of SIRT1 because knockdown of SIRT1 abolishes
the inhibitory effect resveratrol on inflammation [200].
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Figure 4: Schematic diagram of the mechanisms by which resveratrol regulates cutaneous functions. α-SMA: α-smooth muscle actin.
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+us, resveratrol can inhibit cutaneous inflammation via a
variety of mechanisms, including inhibition of NF-κB,
MAPK/p38, phospholipase Cc, and p-mTOR, upregula-
tion of miR-17, and activation of SIRT1.
4.5.WoundHealing. Cutaneous wound healing is a complex
process that can be accelerated by resveratrol via stimulation
of neovascularization, keratinocyte differentiation, perme-
ability barrier maturation, and antimicrobial activity. One
study showed that resveratrol accelerates cutaneous wound
healing and vascularization in aged rats through upregu-
lation of SIRT1 and adenosine monophosphate-activated
protein kinase (AMPK) pathway [121]. +e role of SIRT1
signaling in vascularization has also been demonstrated in
cutaneous wounds of diabetic mice. Topical applications of
resveratrol to the wounded area of diabetic mice stimulated
proliferation and inhibited apoptosis of endothelial cells,
leading to accelerated wound healing, while either SIRT1
inhibitor or knockout of SIRT1 abolished the benefits of
resveratrol in wound healing [125]. SIRT1-mediated benefits
of resveratrol in diabetic wound healing can also be at-
tributable to protection of endothelial cells from oxidative
stress [201]. In addition, studies in mice indicate that
resveratrol accelerates cutaneous wound healing by upre-
gulation of vascular endothelial growth factor mediated by
activation of at least two antioxidant enzymes (thioredoxin-1
and heme oxygenase-1) [123]. Because wound infections are
the major cause of delayed wound healing [202], the anti-
microbial properties of resveratrol could be another
mechanism whereby wound healing is accelerated. Lastly,
the ultimate goal of cutaneous wound healing is the for-
mation of intact permeability barrier, which requires both
lipid production and keratinocyte differentiation. +us,
resveratrol could also accelerate cutaneous wound healing
through its well-known ability to stimulate keratinocyte
differentiation and lipid production [83, 84, 161]. Collec-
tively, the resveratrol-induced acceleration of cutaneous
wound healing can be attributable to activation of SIRT1 and
AMPK signaling, antioxidative stress, and enhanced for-
mation of epidermal permeability barrier.
4.6. Others. +e mechanisms whereby resveratrol induces
apoptosis and inhibition of fibroblasts include inhibition of
hypoxia-inducible factor 1, in which activation stimulates
fibroblast proliferation while inhibiting apoptosis [203],
downregulation of transforming growth factor β1 [169],
miR-17 [204], as well as expression levels of mRNA for
collagen 1 and procollagen 3 [167], whereas resveratrol-
induced upregulation of antimicrobial peptides is via en-
hancing expression of sphingosine-1-phosphate, leading to
activation of N-FκB-C/EBPα signaling pathway [161].
Resveratrol inhibits melanogenesis by at least four dif-
ferent mechanisms: (1) in human melanocyte cultures,
resveratrol inhibited tyrosinase synthesis and activity along
with accelerated transport of newly synthesized tyrosinase to
proteasomal complex, without dramatic alterations in
mRNA levels of either melanocytic microphthalmia-asso-
ciated transcription factor (MIFT) or tyrosinase [205]; (2) in
melan-A cells, inhibition of melanogenesis by resveratrol is
via induction of autophagy, leading to reduction in α me-
lanocyte-stimulating hormone levels [206]. +e latter
stimulates melanin production and release via activation of
melanocortin-1 receptor. Deletion of autophagy-related
genes could prevent resveratrol-induced reduction in me-
lanogenesis; (3) in human melanocyte cultures, resveratrol
activated c-Jun N-terminal kinase, resulting downregulation
of MITF expression [207]; and (4) anti-inflammatory effects
of resveratrol can be an additional mechanism contributing
to decreasing pigmentation [171].+e antioxidant properties
of resveratrol largely account for its antiaging effects [208].
5. Additional Points
Both in vitro and in vivo studies showed that resveratrol
regulates multiple cutaneous functions, including UV pro-
tection, anti-inflammation, antioxidant defense, acceleration
of wound healing, antimicrobe, anticancer, and inhibition of
melanogenesis. Upregulation of SIRT1 largely accounts for
the mechanisms of resveratrol action although various other
mechanisms are also involved. +us, resveratrol benefits
multiple cutaneous functions through a variety of mecha-
nisms. While clinical data have revealed the benefits of
resveratrol for extracutaneous systems/organs, including
improvements in bone density, osteoarthritis, renal function,
and diabetes, evidence is still insufficient to conclude its
benefits for cutaneous functions in clinical settings.+erefore,
proper clinical trials are still required to validate the clinical
significance of the utility of resveratrol in the skin.
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